Navigation Links
NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Date:5/25/2010

PARIS, May 25, 2010 /PRNewswire/ --

- NEVO(TM), Incorporating RES TECHNOLOGY(TM), Continues to Support Excellent Safety and Efficacy Outcomes vs. the Taxus(R) Liberte(R) According to Data Presented at EuroPCR 2010

At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus(R) Liberte(R) according to new data presented today from the NEVO(TM) RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

Through 12-month follow-up, there have been no episodes of stent thrombosis reported in the NEVO(TM) arm, whereas two such events have been reported through 12 months in patients treated with the Taxus(R) Liberte(R) stent, and a third event in this arm was reported after 13 months. Additionally there have been no cases of cardiac death or out-of-hospital myocardial infarction (MI) for patients receiving NEVO(TM).

While the trial was not powered for clinical endpoints and thus no statistically-significant differences were observed, the rates of death, MI, the need for repeat revascularization, and the occurrence of stent thrombosis numerically favored NEVO(TM) over Taxus(R) Liberte(R) to an even greater degree at 12 months than they had at six months. Similar trends were observed in the pre-defined subgroups of patients with diabetes and patients with lesion lengths less than or greater than 20 mm.

At the six-month primary endpoint of this prospective, randomized clinical trial, NEVO(TM) was reported to be superior to Taxus(R) Liberte(R) in in-stent late
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients
2. French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent
3. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
4. New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
5. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Boston Scientific Launches New Coronary Imaging Catheter
8. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
9. LightLab Imaging Leads Global Advancement of Intracoronary Imaging
10. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
11. Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... -- Wockhardt Limited today announces a major boost to ... two of its drugs, WCK 771 and WCK 2349, ... from U.S. Food & Drug Administration (FDA).  QIDP status ... have a high degree of unmet need in their ... (a top U.S. government health and safety body).  QIDP ...
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... CARLSBAD, Calif., Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ... of,Directors has promoted B. Lynne Parshall, J.D. to ... position as Chief Financial,Officer, and is a Director ... and appropriately reflects the scope,of Lynne,s responsibilities at ...
... /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today announced ... its asthma diagnostic tool, Aridol in Portugal., ... included in the,successful mutual recognition procedure earlier this ... "Bronchial challenge testing is a common procedure ...
... Corporation (NYSE:,FMC) and Pronova BioPharma ASA (OSE: ... a worldwide license and development agreement to ... by FMC. The,alginate-based capsule technology is expected ... Pronova BioPharma,s products and has,the potential for ...
Cached Biology Technology:Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3Pharmaxis Appoints Portuguese Distributor for Aridol 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:9/2/2014)... The Field Museum will present the prestigious Parker/Gentry Award ... commitment to biodiversity conservation awareness. The Parker/Gentry Award is ... individual, team or organization whose efforts have had a ... and whose actions can serve as a model to ... an environmental science and conservation news website that draws ...
(Date:9/2/2014)... a history of scientific research on mountain ecosystems, ... systems, and sets an agenda for biodiversity conservation ... "Mountain gloom and mountain glory revisited: A survey ... regions," appears online in the Journal of ... of Tufts University, Jodi A. Hilty of the ...
(Date:9/2/2014)... JUPITER, FL, September 2, 2014 In a new ... scientists from the Florida campus of The Scripps Research ... diseased cells into unique manufacturing sites for molecules that ... using a cell as a reaction vessel and a ... in a diseased cell," said TSRI Professor Matthew Disney.,"Because ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Scripps Florida scientists make diseased cells synthesize their own drug 2
... turtles are too optimistic, according to Loren McClenachan ... McClenachan, Jeremy Jackson and Marah Newman agree ... helped increase green and hawksbill turtle populations that ... that dwindling turtle populations on many historically important ...
... population in New Hampshire's Great Bay estuary has plummeted by ... disease MSX. The previous century saw a slower but equally ... local extinction on some reefs," says Ray Grizzle, research associate ... , Now Grizzle is working to bring oysters back ...
... a surprisingly high percentage of people with type 1 ... years or longer (The Joslin Medalists) may still have ... The findings will be presented June 12 at the ... Washington, D.C. , "It is surprising that some ...
Cached Biology News:All the eggs in one basket 2All the eggs in one basket 3UNH researcher restoring oyster reefs to Great Bay 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 3